- Home
- JOB vs OTLK Comparison
JOB vs OTLK Comparison
Compare JOB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JOB | OTLK |
|---|---|---|
| Founded | 1893 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 29.2M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JOB | OTLK |
|---|---|---|
| Price | $0.25 | $0.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 249.5K | ★ 4.3M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,504,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.16 |
| 52 Week High | $0.28 | $3.39 |
Technical Indicators
Market Signals| Indicator | JOB | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 42.17 |
| Support Level | $0.19 | $0.21 |
| Resistance Level | $0.27 | $0.29 |
| Average True Range (ATR) | 0.01 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 36.64 | 24.53 |
Price Performance
Historical ComparisonAbout JOB GEE Group Inc.
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.